Effect of benralizumab treatment on the airway microbiome in COPD
Background One-third of patients with COPD have an eosinophilic inflammatory phenotype. Benralizumab is an afucosylated humanised monoclonal antibody that targets the interleukin-5 receptor α subunit, leading to rapid and near-complete eosinophil depletion via antibody-dependent cellular cytotoxicit...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
European Respiratory Society
2025-04-01
|
| Series: | ERJ Open Research |
| Online Access: | http://openres.ersjournals.com/content/11/2/00802-2024.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|